Nkarta (NKTX)
(Real Time Quote from BATS)
$7.09 USD
+0.22 (3.20%)
Updated Apr 29, 2024 09:42 AM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NKTX 7.09 +0.22(3.20%)
Will NKTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NKTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NKTX
All You Need to Know About Nkarta, Inc. (NKTX) Rating Upgrade to Buy
Nkarta (NKTX) Rallies 112% as FDA Clears IND for Lupus Drug
NKTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Nkarta, Inc. (NKTX) is Poised for a Turnaround After Losing -39.31% in 4 Weeks
Should You Buy Nkarta (NKTX) Ahead of Earnings?
Wall Street Analysts Predict a 209% Upside in Nkarta, Inc. (NKTX): Here's What You Should Know
Other News for NKTX
Nkarta: Down 50% Since March With A Clinical Catalyst Ahead
Amgen’s Blincyto data send Cullinan higher
Commit To Purchase Nkarta At $5, Earn 31.3% Annualized Using Options
12 Health Care Stocks Moving In Friday's Pre-Market Session
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Nkarta (NKTX)